Single Intravenous Infusion of GC101 TIL Therapy Achieves Complete Clearance of High-Grade Glioblastoma Within 4 Weeks, Sustained Remission Over 20 Months

November 7-9, 2025The 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)The annual meeting is about to officially open in Maryland, USA. The SITC Annual Meeting is one of the world's largest international top-tier events focused on cancer immunotherapy, dedicated to advancing the science and application of cancer immunotherapy, discovering breakthrough progress, and improving the prognosis for all cancer patients.

The latest clinical breakthrough of Juncell Therapeutics' GC101 has also been included. AGrade Ⅳ GlioblastomaPatient's MenstruationJust four weeks after a single infusion of GC101 TIL, the tumor was completely eliminated, and the patient has maintained tumor-free survival for over 20 months.Brings new hope for the treatment of such advanced malignant tumors. This latest breakthrough will be shared synchronously with global industry experts in the form of posters and online.

As one of the most common primary intracranial tumors, glioma is considered a "tough challenge" in the field of oncology due to its high malignancy and strong heterogeneity — traditional surgery combined with radiotherapy and chemotherapy not only struggles to completely eliminate the lesion but also comes with severe side effects. The median survival period for patients is 6-10 months, with a 5-year survival rate of less than 10%. More challenging is the blood-brain barrier, which acts as a "natural barrier," preventing the vast majority of drugs from entering, thereby significantly impacting their therapeutic efficacy.

Relying on Juncell Therapeutics' self-developedDeepTIL™ Technology Platform,Its unique segmented process has achieved key technological innovation. Tumor tissue is obtained from the patient during the initial surgery, and TIL seed cells are pre-stored. Upon recurrence, these cells are rapidly revived, cultured, and reinfused, reducing waiting time while preserving highly active cytotoxic cells.

Conventional IL-2-dependent TIL therapy for glioblastoma has certain limitations: on the one hand, it is difficult to culture clinical-grade TIL cells from "cold tumors"; on the other hand, IL-2 injection may increase the risk of serious adverse reactions such as intracranial edema and cerebral hemorrhage.

Juncell Therapeutics GC101 Innovative TIL TherapyNo lymphodepletion preconditioning required, no IL-2 injection needed, which can autonomously cross the blood-brain barrier after intravenous infusion, precisely targeting and killing tumors. It also offers the advantages of rapid onset, long-lasting effects, and minimal side effects. This breakthrough in the field of glioblastoma isGC101 Following Pancreatic Cancer, Melanoma, Lung Cancer, Gynecological Tumors(Click to review the case report)Another major advancement following various types of cancer,Expected to completely change the treatment landscape of glioblastoma.

At the beginning of 2023, Mr. W was diagnosed with glioblastoma (IDH wild-type, WHO Grade IV, EGFR amplification). This subtype is one of the most malignant and hardest to treat types of glioma, and at the moment of diagnosis, an invisible hand pressed the countdown button on his life.

At the brink of danger, Mr. W first underwent a high-risk brain tumor resection surgery, followed by chemotherapy with temozolomide and radiation therapy post-surgery; however, his condition was not controlled. Subsequently, he tried two different targeted CAR-T therapies, completing more than 10 intratumoral injections in total, yet the tumor deterioration could not be continuously halted.

Patient Treatment History

At the end of 2023, just as Mr. W and his family were falling into despair, a turning point arrived quietly. Mr. W successfully joined the GC101 clinical trial and received TIL cell infusion therapy (the cells were sourced and cultured from his surgery a year prior). Just four weeks after the infusion, imaging showed that the tumor in his brain had been completely eliminated, with the treatment effect assessed as complete remission (CR). There has been no recurrence since, and he has maintained a tumor-free survival state for over 20 months. Today, Mr. W has long been freed from the confines of his hospital bed, reborn, and returned to a hard-earned normal life.

Changes in Patient's Magnetic Resonance Imaging (MRI)

As of now, this case not only刷新了复发性胶质母细胞瘤的生存纪录 (refreshed the survival record for recurrent glioblastoma), but also再次验证了TIL疗法的持久疗效 (once again validated the long-lasting efficacy of TIL therapy) with vivid clinical data, while also providing..."Early Harvest, Reinfusion of TIL After Relapse"Provides critical clinical evidence for treatment strategies, bringing hope to countless patients with solid tumors who are in desperate situations.

Juncell Therapeutics focuses on the development of TIL therapy and has independently established an internationally leadingDeepTIL™ Cell Enrichment and Expansion & NovaGMP® Gene Modification Technology Platform, based on which a series of globally leading TIL innovative therapies have been developed. Two of them have entered the clinical trial stage and are currently recruiting patients with advanced solid tumors from the public.

In the critical Phase II clinical trialsThe world's first product that requires no lymphatic clearance and no IL-2 injectionThe natural TIL therapy GC101, as well as the one currently in Phase I clinical trials,World's First Non-Viral VectorGene-modified TIL therapy GC203 demonstrates excellent clinical efficacy across more than 10 different types of advanced solid tumors (including pancreatic cancer and high-grade glioma that have failed multiple lines of treatment), with tumors in several patients beingComplete Clearance, and maintain the longest tumor-free survivalMore than 4 years。

Juncell Therapeutics will adhere to the noble mission of "Refining Cells, Guarding Lives," embrace the inspiring vision of "Creating Miracles with Science, Turning Miracles into Everyday Realities," and uphold the core values of "Focus, Innovation, Inclusiveness, and Sharing" to make innovative TIL therapies of high clinical value accessible to more cancer patients.

References:

https://pubmed.ncbi.nlm.nih.gov/38769543/

https://ascopubs.org/doi/pdf/10.1200/JCO.2024.42.16_suppl.5552

https://www.brainmed.com/info/detail?id=49249

Disclaimer: The content of this article is only for information sharing and viewpoint presentation, aiming to convey cutting-edge professional information and meet the information needs of medical professionals. It does not intend to promote any products or recommend treatment plans to you.

The GC101 mentioned in this article is currently in the clinical trial stage and has not yet been approved for marketing. Its safety and efficacy remain to be verified. This article only reflects the interim results of the clinical trial and does not imply the product's efficacy, safety, or time of market release.

For any medical behaviors related to the diagnosis and treatment of diseases, please follow the guidance of healthcare professionals.